Pramlintide treatment reduces 24-h caloric intake and meal sizes and improves control of eating in obese subjects: a 6-wk translational research study.

Smith SR, Blundell JE, Burns C, Ellero C, Schroeder BE, Kesty NC, Chen KS, Halseth AE, Lush CW, Weyer C

American journal of physiology. Endocrinology and metabolism15 May 2007Cited by 98 (Europe PMC)

PMID17505051DOI10.1152/ajpendo.00217.2007PepBankPUB-17505051

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanRandomized controlled trialEfficacy outcome
In obese subjects, pramlintide reduced weight from baseline more than placebo at day 44.
In plain wordsIn obese subjects, weight fell more with pramlintide than placebo at day 44.
Peptide
Pramlintide (Symlin)
Outcome
DecreaseBody weight at day 44
Study
n = 88
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
180 microg before meals · subcutaneous · 6 weeksAs given in this study (human).
Measurements
Weight change
−2.1%
pramlintide, day 44
Weight change
0.1%
placebo, day 44
Source sentences
Summary
Compared with placebo, pramlintide treatment elicited significant mean reductions from baseline in body weight on day 44 (-2.1 +/- 0.3 vs. +0.1 +/- 0.4%, P < 0.001)
2 context sentences(design, population, supporting numbers)
Summary · context
To assess the effect of amylin agonism on human eating behavior we conducted a randomized, blinded, placebo-controlled, multicenter study investigating the effects of the amylin analog pramlintide on body weight, 24-h caloric intake, portion sizes, "fast food" intake, and perceived control of eating…
Summary · context
After a 2-day placebo lead-in, subjects self-administered pramlintide (180 microg) or placebo by subcutaneous injection 15 min before meals for 6 wk without concomitant lifestyle modifications.
Report a problemFND-1750505101
02HumanRandomized controlled trialEfficacy outcome
In obese subjects, pramlintide reduced daily caloric intake more than placebo at day 3.
In plain wordsIn obese subjects, daily calorie intake fell more with pramlintide than placebo at day 3.
Peptide
Pramlintide (Symlin)
Outcome
Decrease24-hour caloric intake at day 3
Study
n = 88
Comparator
Placebo
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
180 microg before meals · subcutaneous · 6 weeksAs given in this study (human).
Measurements
Caloric intake change
−990 kcal
pramlintide, day 3
Caloric intake change
−243 kcal
placebo, day 3
Source sentences
Summary
24-h caloric intake (-990 +/- 94 vs. -243 +/- 126 kcal on day 3, P < 0.0001; -680 +/- 86 vs. -191 +/- 161 kcal on day 43, P < 0.01)
2 context sentences(design, population, supporting numbers)
Summary · context
To assess the effect of amylin agonism on human eating behavior we conducted a randomized, blinded, placebo-controlled, multicenter study investigating the effects of the amylin analog pramlintide on body weight, 24-h caloric intake, portion sizes, "fast food" intake, and perceived control of eating…
Summary · context
After a 2-day placebo lead-in, subjects self-administered pramlintide (180 microg) or placebo by subcutaneous injection 15 min before meals for 6 wk without concomitant lifestyle modifications.
Report a problemFND-1750505102
03HumanRandomized controlled trialEfficacy outcome
In obese subjects, pramlintide reduced daily caloric intake more than placebo at day 43.
In plain wordsIn obese subjects, daily calorie intake fell more with pramlintide than placebo at day 43.
Peptide
Pramlintide (Symlin)
Outcome
Decrease24-hour caloric intake at day 43
Study
n = 88
Comparator
Placebo
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
180 microg before meals · subcutaneous · 6 weeksAs given in this study (human).
Measurements
Caloric intake change
−680 kcal
pramlintide, day 43
Caloric intake change
−191 kcal
placebo, day 43
Source sentences
Summary
24-h caloric intake (-990 +/- 94 vs. -243 +/- 126 kcal on day 3, P < 0.0001; -680 +/- 86 vs. -191 +/- 161 kcal on day 43, P < 0.01)
2 context sentences(design, population, supporting numbers)
Summary · context
To assess the effect of amylin agonism on human eating behavior we conducted a randomized, blinded, placebo-controlled, multicenter study investigating the effects of the amylin analog pramlintide on body weight, 24-h caloric intake, portion sizes, "fast food" intake, and perceived control of eating…
Summary · context
After a 2-day placebo lead-in, subjects self-administered pramlintide (180 microg) or placebo by subcutaneous injection 15 min before meals for 6 wk without concomitant lifestyle modifications.
Report a problemFND-1750505103
04HumanRandomized controlled trialEfficacy outcome
In obese subjects, pramlintide significantly reduced portion sizes from baseline versus placebo.
In plain wordsIn obese subjects, portion sizes fell more with pramlintide than placebo.
Peptide
Pramlintide (Symlin)
Outcome
DecreasePortion sizes
Study
n = 88
Comparator
Placebo
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
180 microg before meals · subcutaneous · 6 weeksAs given in this study (human).
Source sentences
Summary
portion sizes, and caloric intake at a "fast food challenge" (-385 +/- 61 vs. -109 +/- 88 kcal on day 44, P < 0.05).
3 context sentences(design, population, supporting numbers)
Summary · context
Compared with placebo, pramlintide treatment elicited significant mean reductions from baseline in body weight on day 44 (-2.1 +/- 0.3 vs. +0.1 +/- 0.4%, P < 0.001)
Summary · context
To assess the effect of amylin agonism on human eating behavior we conducted a randomized, blinded, placebo-controlled, multicenter study investigating the effects of the amylin analog pramlintide on body weight, 24-h caloric intake, portion sizes, "fast food" intake, and perceived control of eating…
Summary · context
After a 2-day placebo lead-in, subjects self-administered pramlintide (180 microg) or placebo by subcutaneous injection 15 min before meals for 6 wk without concomitant lifestyle modifications.
Report a problemFND-1750505104
05HumanRandomized controlled trialEfficacy outcome
In obese subjects, pramlintide reduced caloric intake at the fast food challenge more than placebo at day 44.
In plain wordsIn obese subjects, calories eaten at a fast food challenge fell more with pramlintide than placebo.
Peptide
Pramlintide (Symlin)
Outcome
DecreaseFast food challenge caloric intake
Study
n = 88
Comparator
Placebo
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
180 microg before meals · subcutaneous · 6 weeksAs given in this study (human).
Measurements
Fast food intake change
−385 kcal
pramlintide, day 44
Fast food intake change
−109 kcal
placebo, day 44
Source sentences
Summary
portion sizes, and caloric intake at a "fast food challenge" (-385 +/- 61 vs. -109 +/- 88 kcal on day 44, P < 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
To assess the effect of amylin agonism on human eating behavior we conducted a randomized, blinded, placebo-controlled, multicenter study investigating the effects of the amylin analog pramlintide on body weight, 24-h caloric intake, portion sizes, "fast food" intake, and perceived control of eating…
Summary · context
After a 2-day placebo lead-in, subjects self-administered pramlintide (180 microg) or placebo by subcutaneous injection 15 min before meals for 6 wk without concomitant lifestyle modifications.
Report a problemFND-1750505105
06HumanRandomized controlled trialEfficacy outcome
In obese subjects, pramlintide improved perceived eating control with a 45% placebo-corrected reduction in binge eating scores.
In plain wordsIn obese subjects, pramlintide reduced binge eating scores more than placebo.
Peptide
Pramlintide (Symlin)
Outcome
DecreaseBinge eating score
Study
n = 88
Comparator
Placebo
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
180 microg before meals · subcutaneous · 6 weeksAs given in this study (human).
Measurements
Placebo-corrected binge eating score reduction
45%
pramlintide
Source sentences
Summary
Pramlintide treatment also improved perceived control of eating, as demonstrated by a 45% placebo-corrected reduction in binge eating scores (P < 0.01).
2 context sentences(design, population, supporting numbers)
Summary · context
To assess the effect of amylin agonism on human eating behavior we conducted a randomized, blinded, placebo-controlled, multicenter study investigating the effects of the amylin analog pramlintide on body weight, 24-h caloric intake, portion sizes, "fast food" intake, and perceived control of eating…
Summary · context
After a 2-day placebo lead-in, subjects self-administered pramlintide (180 microg) or placebo by subcutaneous injection 15 min before meals for 6 wk without concomitant lifestyle modifications.
Report a problemFND-1750505106

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.